



## Verastem to Present at 28th Annual ROTH Conference

March 8, 2016

BOSTON--(BUSINESS WIRE)--Mar. 8, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will present at the 28<sup>th</sup> Annual ROTH Conference on Tuesday, March 15 at 12:00 p.m. PT at the Ritz-Carlton in Dana Point, CA.

A live webcast of the presentation will be available on the company's website at [www.verastem.com](http://www.verastem.com). An archived presentation will be available for 90 days.

### About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Our product candidates utilize a multi-faceted approach to treat cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and modulating the local tumor microenvironment. Our most advanced clinical product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584. For more information, please visit [www.verastem.com](http://www.verastem.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160308005397/en/>

Source: Verastem, Inc.

### Verastem, Inc.

Brian Sullivan, 781-292-4214  
[bsullivan@verastem.com](mailto:bsullivan@verastem.com)